Cargando…

Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients

Little is known about Subgenomic RNA (sgRNA) dynamics in patients with Coronavirus diseases 2019 (COVID-19). We collected 147 throat swabs, 74 gut swabs and 46 plasma samples from 117 COVID-19 patients recruited in the LOTUS China trial (ChiCTR2000029308) and compared E and orf7a sgRNA load in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Xiaohui, Mu, Shengrui, Wang, Yeming, Guo, Li, Ren, Lili, Deng, Xiaoyan, Li, Haibo, Zhao, Jiankang, Zhang, Yulin, Li, Hui, Lu, Binghuai, Huang, Chaolin, Cao, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wuhan Institute of Virology, Chinese Academy of Sciences 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762994/
https://www.ncbi.nlm.nih.gov/pubmed/35234623
http://dx.doi.org/10.1016/j.virs.2022.01.008
_version_ 1784633863695237120
author Zou, Xiaohui
Mu, Shengrui
Wang, Yeming
Guo, Li
Ren, Lili
Deng, Xiaoyan
Li, Haibo
Zhao, Jiankang
Zhang, Yulin
Li, Hui
Lu, Binghuai
Huang, Chaolin
Cao, Bin
author_facet Zou, Xiaohui
Mu, Shengrui
Wang, Yeming
Guo, Li
Ren, Lili
Deng, Xiaoyan
Li, Haibo
Zhao, Jiankang
Zhang, Yulin
Li, Hui
Lu, Binghuai
Huang, Chaolin
Cao, Bin
author_sort Zou, Xiaohui
collection PubMed
description Little is known about Subgenomic RNA (sgRNA) dynamics in patients with Coronavirus diseases 2019 (COVID-19). We collected 147 throat swabs, 74 gut swabs and 46 plasma samples from 117 COVID-19 patients recruited in the LOTUS China trial (ChiCTR2000029308) and compared E and orf7a sgRNA load in patients with different illness duration, outcome, and comorbidities. Both sgRNAs were detected in all the three types of samples, with longest duration of 25, 13, and 17 days for E sgRNA, and 32, 28, and 17 days for orf7a sgRNA in throat, gut, and plasma, respectively. A total of 95% (57/60) of patients had no E sgRNA detected after 10 days post treatment, though 86% of them were still E RNA positive. High correlation on titer was observed between sgRNA encoding E and orf7a gene. sgRNA showed similar variation in the standard care and Lopinavir-Ritonavir group. Patients with diabetes and heart diseases showed higher pharyngeal E sgRNA at the first day (P ​= ​0.016 and 0.013, respectively) but no difference at five days after treatment, compared with patients without such commodities. Patients with hypertension and cerebrovascular diseases showed no difference in the pharyngeal sgRNA levels at both one and five days after treatment, compared with patients without these two commodities. E sgRNA levels in the initial infection showed no correlation with the serum antibody against spike, nucleoprotein, and receptor binding domains at ten days later. sgRNA lasted a long period in COVID-19 patients and might have little effect on humoral response.
format Online
Article
Text
id pubmed-8762994
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wuhan Institute of Virology, Chinese Academy of Sciences
record_format MEDLINE/PubMed
spelling pubmed-87629942022-01-18 Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients Zou, Xiaohui Mu, Shengrui Wang, Yeming Guo, Li Ren, Lili Deng, Xiaoyan Li, Haibo Zhao, Jiankang Zhang, Yulin Li, Hui Lu, Binghuai Huang, Chaolin Cao, Bin Virol Sin Research Article Little is known about Subgenomic RNA (sgRNA) dynamics in patients with Coronavirus diseases 2019 (COVID-19). We collected 147 throat swabs, 74 gut swabs and 46 plasma samples from 117 COVID-19 patients recruited in the LOTUS China trial (ChiCTR2000029308) and compared E and orf7a sgRNA load in patients with different illness duration, outcome, and comorbidities. Both sgRNAs were detected in all the three types of samples, with longest duration of 25, 13, and 17 days for E sgRNA, and 32, 28, and 17 days for orf7a sgRNA in throat, gut, and plasma, respectively. A total of 95% (57/60) of patients had no E sgRNA detected after 10 days post treatment, though 86% of them were still E RNA positive. High correlation on titer was observed between sgRNA encoding E and orf7a gene. sgRNA showed similar variation in the standard care and Lopinavir-Ritonavir group. Patients with diabetes and heart diseases showed higher pharyngeal E sgRNA at the first day (P ​= ​0.016 and 0.013, respectively) but no difference at five days after treatment, compared with patients without such commodities. Patients with hypertension and cerebrovascular diseases showed no difference in the pharyngeal sgRNA levels at both one and five days after treatment, compared with patients without these two commodities. E sgRNA levels in the initial infection showed no correlation with the serum antibody against spike, nucleoprotein, and receptor binding domains at ten days later. sgRNA lasted a long period in COVID-19 patients and might have little effect on humoral response. Wuhan Institute of Virology, Chinese Academy of Sciences 2022-01-17 /pmc/articles/PMC8762994/ /pubmed/35234623 http://dx.doi.org/10.1016/j.virs.2022.01.008 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Zou, Xiaohui
Mu, Shengrui
Wang, Yeming
Guo, Li
Ren, Lili
Deng, Xiaoyan
Li, Haibo
Zhao, Jiankang
Zhang, Yulin
Li, Hui
Lu, Binghuai
Huang, Chaolin
Cao, Bin
Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients
title Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients
title_full Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients
title_fullStr Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients
title_full_unstemmed Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients
title_short Characterization of two SARS-CoV-2 subgenomic RNA dynamics in severe COVID-19 patients
title_sort characterization of two sars-cov-2 subgenomic rna dynamics in severe covid-19 patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762994/
https://www.ncbi.nlm.nih.gov/pubmed/35234623
http://dx.doi.org/10.1016/j.virs.2022.01.008
work_keys_str_mv AT zouxiaohui characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients
AT mushengrui characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients
AT wangyeming characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients
AT guoli characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients
AT renlili characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients
AT dengxiaoyan characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients
AT lihaibo characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients
AT zhaojiankang characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients
AT zhangyulin characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients
AT lihui characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients
AT lubinghuai characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients
AT huangchaolin characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients
AT caobin characterizationoftwosarscov2subgenomicrnadynamicsinseverecovid19patients